Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

Not Applicable

• Conditions: Hepatocellular Carcinoma

• Registration Number: NCT03731910
• Lead Sponsor: Seoul National University Hospital

Brief Summary

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-11-04
• Study First Submitted QC: 2018-11-04
• Study First Posted: 2018-11-06
• Study Start: 2018-12-11
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-16
• Last Update Posted: 2021-12-17
• Primary Completion: 2022-12-31
• Study Completion: 2023-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline
• Scheduled for transarterial radioembolization (TARE)
• sign informed consent

Exclusion Criteria

• Any absolute or relative contra-indication of contrast-enhanced MRI
• History of other local treatment before TARE in 3 weeks

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Treatment response mRECIST	1 month after last MRI	treatment response using mRECIST

Secondary Outcome Measures

Name	Time	Method
Tumor diffusion	1 months after last MRI	measured with diffusion-weighted image sequence
Tumor perfusion	1 months after last MRI	measured with dynamic contrast-enhanced imaging
Treatment response LI-RADS	1 months after last MRI	treatment response using LI-RADSv 2018 treatment response category
Treatment response volumetric	1 months after last MRI	treatment response using volumetric response criteria
Time to Progression	24 months after TARE	Time until to definite progression on follow-up images

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of